Sgx-001
Preclinical
Sgx-001 is one of 10 therapeutic programs targeting Chronic Granulomatous Disease (CGD). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
9 competitors in Chronic Granulomatous Disease (CGD)
#DrugCompanyPhaseTrials
1Promacta
GSKPreclinical
Busulfex
Akero TherapeuticsPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Actemra
CCelltrion
Preclinical
Mozobil
GGenzyme, a Sanofi Company
Preclinical
Neupogen
EEastern Cooperative Oncology Group
Preclinical
Kepivance
SSwedish Orphan Biovitrum
Preclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Base-Edited T Lymphocyte Cells
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Sgx-001
SSomagenetix AG
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Granulomatous Disease (CGD)1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Sgx-001. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- SSomagenetix AG